Array BioPharma has achieved a $10 million clinical research milestone in its collaboration with Celgene, with the planned initiation of a Phase I dose escalation trial in cancer patients with ARRY-382, a small molecule cFMS inhibitor. Array is responsible for the continued development of ARRY-382 through Phase I and Celgene has an option to obtain exclusive rights to the drug. If Celgene exercises this option, it would be responsible for further development and commercialization and Array wo...